

Joseph R. Osborne, M.D., Ph.D.
Tel: 212-746-6797 Email: jro7001@med.cornell.edu

EDUCATION:

COLUMBIA UNIVERSITY, New York, N.Y. 1992 - 2001
Ph.D., Integrated Program in Cellular and Molecular Biophysics
Advisor: Richard Axel – Higgins Professor of Biochemistry and Biophysics
2004 Nobel Laureate in Physiology or Medicine

M.D., College of Physicians & Surgeons
Columbia Presbyterian Medical Center

BROWN UNIVERSITY, Providence, R.I. 1988 - 1992
B.S., Neuroscience

POSTDOCTORAL AND MEDICAL TRAINING:

COLUMBIA PRESBYTERIAN HOSPITAL (CPMC), New York, N.Y. 2003 - 2007
DEPARTMENT OF RADIOLOGY – Chief Resident 2006 - 2007

CPMC NUCLEAR MEDICINE SECTION 2007 - 2008
Phillip Johnson Nuclear Radiology Fellow

MEMORIAL SLOAN KETTERING CANCER CENTER, New York, N.Y. 2002 - 2003
DEPARTMENT OF NUCLEAR MEDICINE 2003 - 2007
Post-doctoral fellowship – In vivo Cellular and Molecular Imaging
Advisor: Dr. Steven Larson – Chief of Nuclear Medicine Service

WASHINGTON HOSPITAL CENTER, Washington D.C. 2001 - 2002
INTERNAL MEDICINE DEPARTMENT- Internship

PROFESSIONAL POSITIONS AND EMPLOYMENT:

WEILL CORNELL MEDICAL COLLEGE, New York, N.Y. 2018 - Present
RADIOLOGY DEPARTMENT
Professor of Radiology
Chief – Molecular Imaging & Therapeutics
Program Director – Nuclear Medicine Residency Program

MEMORIAL SLOAN KETTERING CANCER CENTER, New York, N.Y. 2012 - 2018
RADIOLOGY DEPARTMENT
Associate Member – Molecular Imaging and Therapy Service
Associate Vice Chairman of Research – Radiology
Former Director – Molecular Imaging and Therapy Residency/Fellowship Programs

WEILL CORNELL MEDICAL COLLEGE, New York, N.Y. 2008 - 2012
RADIOLOGY DEPARTMENT
Assistant Attending of Radiology - Division of Nuclear Medicine
Director – Nuclear Medicine / Molecular Imaging Residency Program

LICENSURE, BOARD CERTIFICATION:

LICENSURE:

New York State No. 230706
Date of issue 12/5/03. Current registration 12/16 – 12/18
DEA number: FOO186610
NPI number: 1710006283

CERTIFICATION:

American Board of Radiology No.53602, Renewed, Issued 01/18
American Board of Nuclear Medicine No.7875, Expires 11/20

PROFESSIONAL MEMBERSHIPS:

New York Roentgen Society	No. 05024380
American College of Radiology	No. 05024380
Society of Nuclear Medicine	No. 275369
American Association of Cancer Research	No. 244263

INTRAMURAL PROFESSIONAL RESPONSIBILITIES:

WCM

Molecular Imaging Innovations Institute lab for inclusion (MI4)

We have a dual interest in molecular imaging probe development and the genetic/socioeconomic causes of the uneven burden of illness. As it is now known that specific genomic mutations can be exploited for more effective diagnosis and treatment. We will further explore how this is reflected in various subpopulations. We believe that this novel approach will have a significant impact on our patient. From the diagnostic perspective we will continue to have a strong focus on the next generation of molecular imaging probes and will focus on finding means of cost-effective and practical integration. It is our belief that cost effective diagnostics will translate to broader access to more effective therapeutics.

MSKCC

Associate Vice Chair of Research - Radiology

The Associate Vice Chair (AVC) for Research in Radiology is the physician liaison to the Deputy Physician-in-Chief of the organization.

INTRAMURAL ADMINISTRATIVE RESPONSIBILITIES:

Weill Cornell Medical College: Administrative

Program Director, Molecular Imaging Residency Program	2019 – Present
Program Director, Molecular Imaging Residency Program	2011 – 2012
RADI05B: Introduction to Nuclear Medicine Medical Student Elective	2011 – 2012
Associate Director of Nuclear Medicine	2010 – 2012

Weill Cornell Medical College: Institutional Committees

Chair, Radioactive Drug Research Committee	2019 – Present
Formulary and Therapeutics Committee	2011 – 2012
Radioactive Drug Research Committee	2010 – 2013
Data Safety and Monitoring Board	2010 – 2013

MSKCC: Administrative

Molecular Imaging and Therapy Service - Observership Director 2014 - Present
Molecular Imaging and Therapy Service - Medical School Elective Director 2013 - Present
Molecular Imaging and Therapy Service - Training Program Director 2013 - 2016
Molecular Imaging and Therapy Service - Mini-Fellowship Director 2012 - Present

MSKCC: Institutional Committees

Investigational New Drug (IND) Committee – MSKCC 2015 - Present
Cyclotron Steering Committee, WCMC and MSKCC 2011 - 2013

Columbia University: Administrative

ABPM 4701: Anatomy for the Engineer or Physicist, 2009 - 2010
Columbia University Applied Math & Applied Engineering

EXTRAMURAL RESPONSIBILITIES:

NIH MEDI- Study Section Imaging Probes and Contrast agents- IPCA 2019

The Imaging Probes and Contrast Agents [IPCA] study section reviews proposals to develop novel contrast agents of all sorts. Studies typically involve the evaluation of new agents with an emphasis on steps such as synthesis, identification of lead candidates, tracer characterization, safety, dosing, and validation preclinical and clinically.

NYC Metro Committee 10/2017 – Present

Committee members participate in the formulation of fundraising and awareness strategies for the region and identify potential new donors and participate in cultivation and solicitation activities.

NIH Special Emphasis Panels 09/2017

Chair, “Early Phase Clinical Trials in Imaging & Image Guided Interventions” and “Imaging & Biomarkers for Early Detection of Aggressive Cancer”.

Damon Runyon-Rachleff Research Foundation

Innovator Award Committee Reviewer 10/2016 - Present

The Innovation Award is an early career “high-risk/high-reward” mechanism designed to support creative thinking in the best of next generation’s scientists. The accepted proposals are cultivated to impact the thought process of all investigating the prevention, diagnosis and/or treatment of cancer.

SNMMI–FDA Task Force 10/2014 – 2019

The task force was created to create a more efficient and timely approval process for new and non-proprietary radiotracers and radio-therapeutics by the U.S. Food and Drug Administration (FDA).

- 1) To optimize evidentiary requirements for the approval of new radiotracers.
- 2) To optimize evidentiary requirements for the approval of radio-therapeutics.
- 3) To engage FDA in dialogue on SNMMI’s recommendations of possible pathways to improving the review and approval process.
- 4) To improve clinical access and reimbursement for non-approved radiolabeled agents under development (traditional IND) or under an Expanded Access IND.

ACR Nuclear Medicine Guidelines Committee 10/2013 - Present

Chair, ACR Appropriateness criteria for unsealed therapeutic radiopharmaceutical sources.

Physician Sponsored IND

IND #115521 ⁸⁹Zr-J591 for localized prostate cancer. 2012 - 2014

NIH MEDI - Medical Imaging Study Section – Chartered Member

02/2011 - 02/2019

The Medical Imaging [MEDI] Scientific Review Group reviews proposals involving the application and validation of in vivo imaging of humans and animals including early phase clinical studies of medical imaging systems, molecular probes and contrast agents, software, molecular imaging techniques and related technologies. The underlying technologies may be refined and optimized during testing in response to research questions or clinical needs.

CURRENT RESEARCH SUPPORT:

R01 CA201250-01A1 NIH/NCI

08/2016 - 07/2021

¹²⁴I NaI PET: Building Block for Precision Medicine in Metastatic Thyroid Cancer

PI: Larson/Humm/Tuttle

Role: Co-Investigator

R01 CA207645-01, NIH/NCI

07/2016 - 06/2019

A New Technique to Make ⁶⁸Ga-Labeled Pharmaceuticals Widely Available for Clinical Use

PI: Osborne

Role: PI

COMPLETED RESEARCH SUPPORT:

Osborne Innovation Fund – Office of the MSK COO

08/2016 - Present

Introducing a Cultural and Linguistic Responsiveness Training Intervention to the Molecular Imaging and Therapy Service (MITS)

Role: PI

P30 CA008748-50 S4 NIH/NCI (EWOFF)

09/2016 - 06/2018

Bedford-Stuyvesant & Bushwick: Cancer Health Impact Program (CHIP)

Role: PI/Project Leader

Clinical Translational Science Center (CTSC)

06/2015 - 05/2016

PVT1 Exon 9 and Aggressive Prostate Cancer in Black Men

PI: Ogunwobi

Role: Co-Investigator

P30 CA008748, MSKCC SOAR Network

09/2014 - 08/2015

Aging-Related Genes, Cognitive Functions, and Amyloid Imaging in Brain Tumor Patients

PI: Correa

Role: Co-PI

1 R21 CA153177-01, NIH/NCI

09/2011 - 09/2013

Immuno-PET with Anti-PSMA ⁸⁹Zr-J591 mAb For Molecular Imaging of Prostate Cancer

Role: PI

National Institute on Aging (5RC2AG036502-02)

09/2011 - 08/2012

Imaging Neuro Inflammation in Alzheimer's Disease with [¹⁴C] Arachidonic Acid

PI: Vallabhajosula

Role: Co-Investigator

R01 MH79397-3, National Institute of Mental Health (NIMH)

01/2011 - 02/2013

Imaging Brain Dopamine (DA) D2 Receptors in Patients with Anorexia Nervosa (AN) Using [¹⁴C]

Raclopride-PET

Role: PI (Subcontract)

U54 CA137788, NIH/NCI (Submitting for Renewal)
MSKCC/CCNY Center of Excellence for Disparities Research.
MPIs: Ahles/Hubbard
Role: Co-Investigator Advisory Committee

09/2008 - 08/2018

5 P50 CA086438-12, NCI
MSKCC Center for Molecular Imaging in Cancer
MPIs: Larson/Blasberg
Role: Executive Committee and Training Program Leader

06/2000 - 06/2016

PEER REVIEWED PUBLICATIONS:

1. Gogos JA, **Osborne J**, Nemes A, Mendelsohn M, Axel R. *Genetic ablation and restoration of the olfactory topographic map*. Cell. 2000; 03(4):609-20.
2. Eggan K, Baldwin K, Tackett M, **Osborne J**, Gogos J, Chess A, Axel R, Jaenisch R. *Mice cloned from olfactory sensory neurons*. Nature. 2004; 428 (6978):44-9.
3. Yu CR, Power J, Barnea G, O'Donnell S, Brown HE, **Osborne J**, Axel R, Gogos JA. *Spontaneous neural activity is required for the establishment and maintenance of the olfactory sensory map*. Neuron. 2004; 42(4):553-66.
4. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, **Osborne JR**, Buchanan IM, Hall S1, Heston WD, Riviere I, Larson SM, Koutcher A, Sadelain M. *Targeted elimination of prostate cancer by genetically directed human T lymphocytes*. Cancer Res. 2005; 65(19):9080-8.
5. Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith S1, **Osborne J**, Matulich D, Petrillo K, Parmar S, Nanus OM, Bander NH. *Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer*. Cancer. 2010;116(4 Suppl):1075-83.
6. Shih G, Lu ZF, Zabih R, Kennedy D, Loftus M, Shih W1, **Osborne J**, Nickoloff E, Schwartz L. *Automated framework for digital radiation dose index reporting from CT dose reports*. AJR Am J Roentgenol 2011;197(5):1170-4.
7. Palaskas N, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, Campos C, Yannuzzi N, **Osborne JR**, Linkov I, Kastenhuber ER, Taschereau R, Plaisier SB, Tran C, Heguy A; Wu H, Sander C, Phelps ME, Brennan C, PortE, Huse JT, Graeber TG, Mellinghoff IK. *18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers*. Cancer Res. 2011; 71(15):5164-74.
8. Wilson SR, Leonard JP, Geyer JT, **Osborne JR**, Weinsaft JW. *A worrisome interventricular septum: more than meets the eye*. J Am Coll Cardiol. 2011; 58(24):e43.
9. Butler T, Ichise M, Teich AF, Gerard E, **Osborne J**, French J, Devinsky O, Kuzniecky R, Gilliam F, Pervez F, Provenzano F, Goldsmith S, Vallabhajosula S, Stem E, Silbersweig D. *Imaging Inflammation in a Patient with Epilepsy Due to Focal Cortical Dysplasia*. J Neuroimaging. 2013; 23(1):129-31.
10. **Osborne JR**, Spratt DE, Green DA, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis J, Christos P, Larson SM, Bander NH, Scherr DS. *A Pilot Study of 89Zr-J591/PSMA Positron Emission Tomography (PET) in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy*. J Urol. 2014;1(5):1439-45.

11. Vallabhajosula S, Nikolopoulou A, Babich JW, **Osborne JR**, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ. *^{99m}Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate*. J Nucl Med. 2014; Nov, 55(11):1791-8.
12. Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, **Osborne JR**, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM. *⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer*. Eur J Nucl Med Mol Imaging. 2014; Nov, 41(11):2093-105.
13. Elstrom RL, Ruan J, Christos PJ, Martin P, Lebovic D, **Osborne J**, Goldsmith S, Greenberg J, Furman RR, Avram A, Putman R, Chapman E, Mazumdar M, Griffith K, Coleman M, Leonard JP, Kaminski MS. *Phase I study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with (131)I-tositumomab*. Leuk Lymphoma. 2015; 56(2):342-6.
14. Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gonen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, **Osborne JR**, Lewis JS, Reuter V, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ. *A Phase I/II Study for Analytic Validation of ⁸⁹Zr-J591 Immuno PET as a Molecular Imaging Agent for Metastatic Prostate Cancer*. Clin Cancer Res. 2015; 21(23):5277-85.
15. Sofocleous CT, Violari EG, Sotirchos VS, Shady W, Gonen M, Pandit-Taskar N, Petre EN, Brody LA, Alago W, Do RK, D'Angelica MI, **Osborne JR**, Segal NH, Carrasquillo JA, Kemeny NE. *Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes*. Clin Colorectal Cancer. 2015; Dec. 14, (4):296-305.
16. Parsons M, Goldman D, Dashevsky B, Riedl CC, Gonen M, **Osborne J**, Jochelson M, Hudis C, Morrow M, Ulaner G. *Value of ¹⁸F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Breast Cancer (ILC) as Compared with Invasive Ductal Breast Cancer (IDC)*. J Nucl Med. 2015; 56(11):1674-80.
17. Spratt DE and **Osborne JR**. *Disparities in Castrate-Resistant Prostate Cancer Clinical Trials*. J Clin Oncol. 2015 Apr 1;33(10):1101-3.
18. **Osborne JR**. *Guest Editorial*. Semin Nucl Med. 2016 Jan;46(1):3-4.
19. Arevalo-Perez J, Paris M, Graham MM, **Osborne JR**. *A Perspective of the Future of Nuclear Medicine Training and Certification*. Semin Nucl Med. 2016 Jan;46(1):88-96.
20. **Osborne JR**, Beylergil V, Samitt C, Graham MM. *Roundtable on the Future of Nuclear Medicine Training*. J Nucl Med. 2015 Dec;56(12):PMID: 26429952.
21. Spratt DE, Perez JA, Leeman JE, Gerber NK, Folkert M, Taunk NK, Alektiar KM, Karimi S, Lyo JK, Tap WD, Bilsky MH, Laufer I, Yamada Y, **Osborne JR**. *Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases*. Spine J. 2016; 16 (3): 291-8.
22. Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR, Bander NH, Larson SM, Zanzonico PB, **Osborne JR**. *Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling*. EJNMMI research. 2016; 6(1):7.

24. Spratt Das DK, Naidoo M, Ilboudo A, Park JY, Ali T, Krampis K, Robinson BD, **Osborne JR**, Ogunwobi OO. *miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin*. Experimental cell research. 2016; 348(2):190-200.
25. Spratt, DE, **Osborne JR**, Zumsteg ZS, Rebeiz K, Leeman J, Rivera A, Morris MJ, Zelefsky MJ. *Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease*. Prostate Cancer Prostatic Dis. 2016; 19(3):271-6.
26. Spratt DE, Chan T, Waldron L, Speers C, Feng FY, Ogunwobi OO, Osborne JR. *Racial/ Ethnic Disparities in Genomic Sequencing*. JAMA Oncol. 2016; 2(8): 1070-4.
27. Leeman JE, Bilsky M, Laufer I, Folkert MR, Taunk NK, **Osborne JR**, Arevalo-Perez J, Zatzky J, Alektiar KM, Yamada Y, Spratt DE. *Stereotactic body radiotherapy for metastatic spinal sarcoma: a detailed patterns-of-failure study*. J Neurosurg Spine. 2016 Jul; 25(1):52-8.
28. Das DK, **Osborne JR**, Lin HY, Park JY, Ogunwobi OO. *miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer*. Transl Oncol. 2016 ;9(3):236-41.
29. Shady W, Kishore S, Gavane S, Do RK, **Osborne JR**, Ulaner GA, Gonen M, Ziv E, Boas FE, Sofocleous CT. *Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0*. Eur J Radiol 2016; 85(6):1224-31.
30. Spratt DE, Beadle BM, Zumsteg ZS, Rivera A, Skinner HD, **Osborne JR**, Garden AS, Lee NY. *The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study*. Int J Radiat Oncol Biol Phys. 2016 1; 94(3):523-31.
31. Spratt D, Zaki BI, Franc BL, Hartford AC, **Osborne JR**. *ACR Practice Parameter for the Performance of Therapy with Unsealed Radiopharmaceutical Sources*. Clin Nucl Med. 2016; 41 (2):106-17.
32. Spratt DE, Chen YW Mahal BA, **Osborne JR**, Zhao SG, Morgan TM, Palapattu G, Feng FY, Nguyen PL. *Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes*. European Urology Focus, In Press, online 1 2016.
33. Das DK, Naidoo M, Ilboudo A, Park JY, Ali T, Krampis K, Robinson BD, **Osborne JR**, Ogunwobi OO. *miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin*. Exp Cell Res. 2016 Nov 1;348(2):190-200.
35. Soliman M, Taunk, NK, Simons, R.E., **Osborne, JR**, Kim, MM, Szerlip, NJ, Spratt, DE. *Anatomic and functional imaging in the diagnosis of spine metastases and response assessment after spine radiosurgery* Neurosurgical Focus. Jan 2017 / Vol. 42 / No. 1, Page E5.
37. Wahl DR, Nguyen PL, Santiago M, Yousefi K, Davicioni E, Shumway DA, Speers C, Mehra R, Feng FY, **Osborne JR**, Spratt DE. *Pan-Cancer Analysis of Genomic Sequencing in the Elderly*. Int J Radiat Oncol Biol Phys. 2017 Jan 7.
38. Spratt DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, **Osborne JR**, Pei X, Zelefsky MJ. *Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage*. Eur Urol. 2017 Jan;71(1):37-43.
39. Larson SM, **Osborne JR**, Grewal RK, Tuttle RM. *Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer*. Mol Imaging Radionucl Ther. 2017 Feb 9;26(Suppl 1):80-86.

40. Wahl DR, Nguyen PL, Santiago M, Yousefi K, Davicioni E, Shumway DA, Speers C, Mehra R, Feng FY, **Osborne JR**, Spratt DE. *Pan-Cancer Analysis of Genomic Sequencing Among the Elderly*. *Int J Radiat Oncol Biol Phys*. 2017 Jul 15;98(4):726-732.
41. Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, Hofree M, Romanel A, **Osborne JR**, Kim JW, Azabdaftari G, Woloszynska-Read A, Sfanos K, De Marzo AM, Demichelis F, Gabriel S, Van Allen EM, Mesirov J, Tamayo P, Rubin MA, Powell IJ, Garraway LA. *Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations*. *Cancer Discov*. 2017 Sep;7(9):973-983.
42. Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, **Osborne JR**, Veach D, Sawyers CL, Weber WA, Scher HI, Morris MJ, Larson SM. *Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer*. *JAMA Oncol*. 2017 Nov 9.
43. Correa DD, Kryza-Lacombe M, Zhou X, Baser RE, Beattie BJ, Beiene Z, Humm J, DeAngelis LM, Orlow I, Weber W, **Osborne J**. *A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas*. *J Neurooncol*. 2017 Nov 22.
44. **Osborne JR**, Kalidindi TM, Punzalan BJ, Gangangari K, Spratt DE, Weber WA, Larson SM, Pillarsetty NVK. *Repeatability of [68Ga] DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer*. *Mol Imaging Biol*. 2017 Dec;19(6):944-951.
45. Costas-Muniz R, Amir J, Paris M, Spratt D, Arevalo-Perez J, Fareedy S, González CJ, Gany F, Camacho-Rivera M, **Osborne JR**. *Interventional Cultural and Language Assistance Program: Associations between Cultural and Linguistic Factors and Satisfaction with Cancer Care*. *J Community Med Health Educ*. 2017;7(1). pii: 503. doi: 10.4172.
46. Ramirez-Fort MK, Mahase SS, **Osborne JR**, Lange CS. *Theragnostic Target, Prostate-Specific Membrane Antigen-Also Specific for Nonprostatic Malignancies*. *Int J Radiat Oncol Biol Phys*. 2018 Jul 1;101(3):646-649. doi: 10.1016/j.ijrobp.2018.03.061. Epub 2018 Apr 5. No abstract available. PMID: 29893276.
47. Camacho-Rivera M, Rice SL, Oh S, Paris M, Akpara E, Molina J, Obadina M, Mcmillan S, Aracena JLM, Morency J, Muniz RC, Gany F, Brown CL, Gonsky J, **Osborne JR**. *Cancer Health Impact Program (CHIP): Identifying Social and Demographic Associations of mHealth Access and Cancer Screening Behaviors Among Brooklyn, New York, Residents* *Cancer Epidemiol Biomarkers Prev*. 2019 Mar;28(3):478-485. Epub 2019 Feb 7. PMID: 30733308.
48. Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, **Osborne J**, Beltran H, Molina AM, Goldsmith SJ, Bander NH, Nanus DM. *Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer*. *Cancer*. 2019 Apr 23.
49. Fridman, Esteban A., **Osborne, Joseph R.**, Mozley, Paul D., Jonathan Victor D, Schiff Nicholas D. *Presynaptic dopamine deficit in minimally conscious state patients following traumatic brain injury*. *Brain*. 2019 Jul 1; 142 (7):1887-1893. doi: 10.1092/bran/awz118.
50. Chaker S, Al-Dasuqi K, Baradaran H, Demetres M, Delgado D, Nehmeh S, **Osborne JR**, Christos PJ, Kamel H, Gupta A. *Carotid Plaque Positron Emission Tomography Imaging and Cerebral Ischemic Disease*. 2019 Aug;50(8):2072-2079. doi: 10.1161/STROKEAHA.118.023987. Epub 2019 Jul 5.

51. **Osborne, Joseph R.**, Kondraciuk, Jessica D., Rice, Samuel L., Zhou, Xiaosun., Knezevic, Andrea., Spratt, Daniel E., Sabra, Mona., Larson, Steven M., Grewal, Ravinder K., *Thyroid cancer brain metastasis: survival and genomic characteristics of a large tertiary care cohort*. *Clinical Nuclear Medicine*. 2019 Jul;44(7):544-549. doi: 10.1097.
52. Dess, Robert T., Hartman, Holly E., Mahal, Brandon A., Paval D., Jackson, William C., Cooperberg, Matthew R., Amling, Christopher L., Aronson, William J., Kane, Christopher J., Terris, Martha K., Zumsteg, Zachary S., Butler, Santino., **Osborne, Joseph R.**, Morgan, Todd M., Mehra, Rohit., Salami, Simpa S., Kishan, Amar U., Wang, Chenyang., Schaefer, Edward M., Roach III, Mack; Pisansky, Thomas M., Shipley, William U., Freedland, Stephen J., Sandler, Howard M., Halabi, Susan., Feng, Felix Y., Dignam, James J., Nguyen, Paul L., Schipper, Matthew J., Spratt, Daniel E., *Association of Black Race with Prostate Cancer–Specific and Other-Cause Mortality*. *Jama Oncology*. 2019 Jul 1;5(7):975-983. doi: 10.1001/jamaoncol.2019.0826.
53. Ivanidze, Jana., Roytman, Michelle., Sasson, Arielle., Skafida, Myrto., Fahey, Thomas J III., **Osborne, Joseph R.**, Dutruel, Silvina P., *Molecular imaging and therapy of somatostatin receptor positive tumors. Clinical Imaging*. In press. 2019 Jul 1;5(7):975-983. doi: 10.1001/jamaoncol.2019.0826.
54. Kondraciuk, Jessica D., Rice, Samuel L., Zhou, Xiaosun., Gharzeddine, Karem., Knezevic, Andrea., Spratt, Daniel E., Sabra, Mona., Larson, Steven M., Grewal, Ravinder K., **Osborne, Joseph R.** *Thyroid cancer bone metastasis: Survival and genomic characteristics of a large tertiary care cohort*. *Clinical Nuclear Medicine*. 2019 Aug; 44(8): e465-e471. Doi: 10.1097.
55. Ivanidze, Jana., Roytman, Michelle., Eaton, Lin., Magge, Rajiv S., Pisapia, David., Liechty, Benjamin., Karakatsanis, Nicholas., Ramakrishna, Rohan., Knisely, Jonathan., Schwartz, Theodore H., **Osborne, Joseph R.**, Pannullo, Susan C., *Gallium-68-DOTATATE PET/MRI in the Diagnosis and Management of Intracranial Meningiomas*. *Journal of Neuroimaging*. 2019 Sep; 29(5):650-656. doi: 10.1111/jon.12632. Epub 2019 May.
56. Niaz MJ, Batra JS, Walsh RD, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, **Osborne JR**, Bander NH, Tagawa ST. *Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer*. *Oncologist*. 2020 Jan 30. doi: 10.1634/theoncologist.2020-0028.
57. Klingensmith WC 3rd, **Osborne JR.**, *George de Hevesy in America*. *J Nucl Med*. 2020 Feb;61(2):304-305. doi: 10.2967/jnumed.119.233254. Epub 2019 Jul 13.